Scleromyxedema - Thalidomide therapy

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 5, 2008, Pages 622-624

  Martins, Andrea ^a,c   Paiva Lopes, M J ^a   Tavares Belo, R ^b   Rodrigues, J C ^a  

^a HOSPITAL DOS CAPUCHOS   (Portugal)

^b Hospital Militar de Belem   (Portugal)

^c NONE   (Portugal)

Author keywords

Paraproteinemia; Scleromyxedema; Thalidomide

Indexed keywords

DEFLAZACORT; ETRETIN; TACROLIMUS; THALIDOMIDE;

AGED; ALOPECIA; ANOREXIA; CASE REPORT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HAND MOVEMENT; HUMAN; HUMAN TISSUE; JOINT LIMITATION; LABORATORY TEST; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; PAPULE; PRIORITY JOURNAL; PRURITUS; SCLEROMYXEDEMA; SKIN BIOPSY; TREATMENT OUTCOME; WEAKNESS;

AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SCLEROMYXEDEMA; SKIN; THALIDOMIDE;

EID: 42149118923     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02420.x     Document Type: Letter

References (6)

1. Bolognia JL, Jorizzo JL, Rapin RP. Dermatology. Mucinosis 2003; 1: 647-658.
2. Okafor MC. Thalidomide for erythema nodosum leprosum and other applications. Pharmacotherapy 2003; 23: 481-493.
3. Dinnen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33: 37-43.
4. Sansbury J, Cocuroccia B, Jorizzo JL et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51: 126-131.
5. Burns T, Breathnach S, Cox N, Griffiths C. Rook's Textbook of Dermatology. Blackwell Publishing, Oxford; 2004, pp. 57.23-57.26.
6. Nasca MR, Micali G, Cheigh NH, West LE, West DP. Dermatologic and nondermatologic uses of thalidomide. Ann Pharmacother 2003; 37: 1307-1320.